The remarkable success of peptide therapeutics, including newer peptide-based GLP-1 receptor agonists, has led to skyrocketing demand for these treatments in recent years.
Their targeted action and reduced side-effect profiles have pushed the global peptide therapeutics market to $43.04 billion in 2023, with projections rising to $81.48 billion by 2032.1,2
As demand grows, purification strategies become increasingly important in programme success. Laurence Pegon, Head of R&D at Novasep CDMO — an Axplora company — reports.
The challenges of peptide manufacturing
One of the inherent challenges in peptide manufacturing is the instability of peptides, which are prone to enzymatic degradation and chemical modifications.
This can result in altered binding and the formation of toxic by-products, subsequently increasing costs and complicating therapy development.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.